HER2 Biomarkers
News and reporting on HER2 biomarkers.
FDA Approves AstraZeneca, Daiichi Sankyo's Datroway for HR-Positive, HER2-Negative Breast Cancer
This marks the first US approval for AstraZeneca and Daiichi Sankyo's Trop-2-directed antibody drug conjugate.
Eli Lilly to Acquire Scorpion Therapeutics' Mutant PI3Kα Inhibitor for $2.5B
Lilly recently terminated its own mutant PI3Kα inhibitor program following disappointing Phase I results.
NICE Recommends Lynparza for BRCA1/2-Mutant Breast Cancer
The institute originally began reviewing Lynparza in this setting in 2018 but ended its review due to lack of evidence.
Biomarker-Targeted Therapy in 2025: Precise Patient Selection, MRD, Antibody-Drug Conjugates
Premium
The already crowded field of biomarker-targeted drugs is poised to only get busier with new biomarkers, ADCs, and cancer vaccines.
FDA Issues Draft Guidance on Tissue Biopsies in Clinical Trials
The agency affirmed the use of biopsies for biomarker-driven trials but cautioned against optional biopsies that offer little value to the patient or trial.
Dec 13, 2024
Nov 25, 2024